High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
about
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsTargeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms.MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis.
P2860
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
@en
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
@nl
type
label
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
@en
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
@nl
prefLabel
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
@en
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
@nl
P2093
P2860
P1433
P1476
High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias
@en
P2093
E Montefusco
F Mandelli
M T Petrucci
R Latagliata
P2860
P304
P356
10.1007/S00277-003-0693-2
P577
2003-06-26T00:00:00Z